Drugs / NMD670
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06482437 | Sep 2024 → Oct 2025 | Charcot-Marie-Tooth disease | NMD Pharma A/S | Completed | No outcome recorded |
| Phase 2 | NCT06414954 | May 2024 → Dec 2026 expected | muscle-specific tyrosine kinase-associated myasthenia gravis | NMD Pharma A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT05794139 | Sep 2023 → May 2026 | spinal muscular atrophy | NMD Pharma A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NMD670 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06414954 ↗ |
| Route | Oral | “Tablets taken twice a day for 21 days” NCT06414954 ↗ |